-+ 0.00%
-+ 0.00%
-+ 0.00%

Chemed (CHE) Stock May Be 26% Undervalued Despite Hospice Billing Scrutiny

Simply Wall St·11/15/2026 07:27:42
Listen to the news

Chemed has logged a strong year so far, and the stock's climb puts a spotlight on a simple question for investors who care about fundamentals. Are the cash flows from its underlying hospice and plumbing services businesses enough to justify where the share price now trades?

  • With a year to date return of 29.4%, Chemed has created meaningful paper gains for shareholders. That raises the stakes on whether current cash flows can support that higher valuation bar.
  • Fresh scrutiny of VITAS Healthcare's Medicare billing practices may influence expectations for future hospice cash generation, since any change in reimbursement oversight or enrollment patterns can affect how reliably those cash flows show up over time.
  • Prefer to judge Chemed on earnings? See why Chemed's 25.2x P/E tells a different valuation story.

The issue now is whether Chemed's recent share price strength is supported by the intrinsic value suggested by its cash flows.

If questions around Chemed's hospice cash flows have you reassessing risk, a focused stock screen can give you a cleaner comparison set through 29 resilient stocks with low risk scores.

Is Chemed Still Cheap on Cash Flow?

The Discounted Cash Flow (DCF) model here focuses on the cash Chemed can return to shareholders over time. Latest twelve month free cash flow sits at about $301.5 million, and the forecast used in this model assumes that future cash generation grows, with 2027 projected above the current level. That points to a business where both hospice and plumbing operations are treated as steady cash engines rather than a turnaround story.

The projections imply that if those cash flows materialize as modeled, the estimated intrinsic worth comes out meaningfully above the current share price of $548.20. The recent investigation into VITAS Medicare billing practices helps explain why the market might still hold the stock below what the cash flow outlook suggests, since investors can price in an extra margin of safety around regulatory risk. For readers who want to see how the detailed cash flow math compares to the current quote, the full DCF breakdown sits behind. Find out what Chemed could be worth using our Discounted Cash Flow (DCF) estimate.

The Chemed Narrative: What Would Justify Today's Price?

Chemed’s recent cash flow puzzle sets up the role of Simply Wall St Narratives, which explain what would need to happen to future growth, margins and earnings for the stock to look meaningfully higher or lower than today’s share price. These narratives sit on the Simply Wall St Community page. Each narrative ties a specific fair value to a clear storyline about Chemed's potential catalysts and key risks so you can track over time which version of events is actually unfolding.

One of the top narratives on Chemed: 19% undervalued

This Narrative is the bullish analyst Narrative on Simply Wall St, built on the most optimistic analyst price target and forecasts, not one person's view.

"The main thing that has to go right is that VITAS manages tighter hospice oversight and audit activity without material profit erosion while Roto-Rooter offsets higher digital marketing costs and integrates reacquired franchises…"

Discover why this Narrative puts Chemed at 19% undervalued.

One more piece of Chemed's story investors often overlook

Chemed’s cash flow profile only tells part of the story, since Simply Wall St’s broader checks have also highlighted specific risk markers that some investors may want to weigh before getting comfortable. Take a closer look at 1 warning sign before settling on a valuation.